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The purpose of the study was to establish the optimal dose of capecitabine (X) to be used within a multicentre, randomised study
evaluating the potential roles of oxaliplatin (O) and X in chemonaive patients (pts) with advanced oesophagogastric cancer. Two
by two design was used, and pts were randomised to one of four regimens and stratified for extent of disease, performance status
(PS) and centre. The treatment regimens are epirubicin, cisplatin, 5-fluorouracil (ECF), EOF, ECX or EOX. Doses: E 50mgm
 2,
C6 0m gm
 2 and O 130mgm
 2 i.v. 3 weekly; F 200mgm
 2day
 1 i.v. and X 500mgm
 2b.i.d.
 1 (escalated to 625mgm
 2b.i.d.
 1
after results of first interim analysis) p.o., continuously. First interim analysis was performed when 80 pts had been randomised. Dose-
limiting fluoropyrimidine toxicities were stomatitis, palmar plantar erythema (PPE) and diarrhoea; 5.1% of X-treated pts experienced
grade 3/4 toxicity. Protocol planned dose escalation of X to 625mgm
 2b.i.d.
 1 was instituted and a second interim analysis has been
performed; results are presented in this paper. A total of 204 pts were randomised at the time of the protocol planned 2nd interim
analysis. Grade 3/4 fluoropyrimidine-related toxicity was seen in 13.7% pts receiving F, 8.4% pts receiving X 500mgm
 2b.i.d.
 1 and
14.7% pts receiving X 625mgm
 2b.i.d.
 1. Combined complete and partial response rates were ECF 31% (95% CI 18.7–46.3), EOF
39% (95% CI 25.9–53.1), ECX 35% (95% CI 21.4–50.3), EOX 48% (95% CI 33.3–62.8). Grade 3/4 fluoropyrimidine toxicity
affected 14.7% of pts treated with X 625mgm
 2b.i.d.
 1, which is similar to that observed with F, confirming this to be the optimal
dose. The replacement of C by O and F by X does not appear to impair efficacy. The trial continues to total accrual of 1000 pts.
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Oesophagogastric (OG) cancer is the second most common cancer
worldwide and while the incidence of gastric cancer is falling, that
of adenocarcinoma of the OG junction is rising. The majority of
pts present with inoperable or metastatic disease and consequently
5-year survival rates are only 10–15% (CRC, 1995). In advanced
disease, palliative chemotherapy has been shown to improve
survival and quality of life (QOL) when compared to best-
supportive care alone (Murad et al, 1993; Pyrhonen et al, 1995;
Glimelius et al, 1997).
One of the reference regimens for this disease is epirubicin,
cisplatin and protracted venous infusion 5-fluorouracil (ECF)
(Cunningham et al, 1991). This regimen was developed at the
Royal Marsden Hospital, and in phase II studies response rates of
55–67% were observed (Evans et al, 1992; Harper et al, 1992;
Melcher and Maughan, 1994; Zaniboni et al, 1995; Bamias et al,
1996). ECF, when compared to FAMTX in a prospective
randomised clinical trial (RCT), demonstrated superior response
rates (45 vs 21%), overall survival and QOL (Webb et al, 1997).
A further RCT comparing ECF to MCF (substituting E with
mitomycin C) confirmed similar efficacy for the two regimens:
response rates ECF 42.2% and MCF 44.1% (P¼0.692) and median
survival 9.4 and 8.7 months, respectively (P¼0.315). Global QOL,
however, was superior with ECF (Ross et al, 2002).
Oxaliplatin (O) is a third-generation diaminocyclohexane
platinum compound, proven to be active in various tumour types.
Oxaliplatin has demonstrated synergy with 5-fluorouracil (5FU)
in advanced colorectal cancer (Raymond et al, 2001). In the first-
line treatment of advanced colorectal cancer, the combination of
O and 5FU has response rates of 36–58% (Levi et al, 1992, 1994;
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sDe Gramont et al, 2000) and this is now an established treatment
in this setting (Goldberg et al, 2004). In addition, activity of this
combination has been demonstrated in advanced gastric cancer,
with a response rate of 45% and a median overall survival of 8.6
months (Louvet et al, 2002). Also, in 26 pts previously treated with
5FU, with a bimonthly O and 5FU/LV bolus and infusional regimen,
the response rate was 26% and the median overall survival was 7.3
months (Kim et al, 2003). Cisplatin is associated with peripheral
neuropathy, renal toxicity, high frequency nerve deafness and
emesis; it also requires intravenous hydration. Oxaliplatin does not
cause any clinically significant renal toxicity or ototoxicity and the
dose-limiting toxicity is a peripheral sensory neuropathy, which is
usually reversible but cumulative. The unique activity of O in
colorectal cancer, the preliminary interesting results in gastric
cancer and its improved toxicity profile compared to cisplatin
suggest the potential for improved results in OG cancer.
Capecitabine (X) is an oral fluoropyrimidine, which is absorbed
from the gastrointestinal tract as an intact molecule, metabolised
primarily in the liver and converted in tumour tissues to 5FU by
the enzyme thymidine phosphorylase (found in higher concentra-
tions in tumour cells than normal cells). In advanced colorectal
cancer, two RCTs have shown X to be at least as effective as 5FU/
LV (Mayo regimen) in terms of overall survival, with a better
toxicity profile (Hoff et al, 2001; Van Cutsem et al, 2001).
Capecitabine is known to be active in advanced gastric cancer, with
a single agent response rate in chemonaive pts of 24% (Koizumi
et al, 2003). A phase II study involving X 1250mgm
 2day
 1 D1–
14 and cisplatin 60mgm
 2day
 1 D1 every 3 weeks, for first-line
treatment of advanced gastric cancer, resulted in an overall
response rate of 54% and a median survival of 10.1 months (Kim
et al, 2002).
To achieve the synergistic effects of fluoropyrimidines in
combination with platinum compounds, thymidylate synthase
inhibition is required prior to platinum administration (Cho et al,
2002). Preclinical studies have confirmed that a twice daily dosing
of X will ensure efficient thymidylate synthase inhibition. A
continuous twice daily X monotherapy schedule has been studied
in a phase I trial (Budman et al, 1998). The maximum tolerated
dose was 1657mgm
 2day
 1 and the recommended dose for phase
II studies was 1331mgm
 2day
 1. The conclusions of a phase I
study of the combination of O and X in advanced solid tumours
recommended a dose of X 1000mgm
 2b.i.d.
 1 D1–14 (80% of the
monotherapy dose) in combination with O 130mgm
 2 every 3
weeks (Diaz-Rubio et al, 2002). The dose-limiting toxicity of the
combination was diarrhoea and the combination resulted in
limited additional haematological toxicity.
In this study, it was not expected that the proposed starting
dose of X of 500mgm
 2b.i.d.
 1 continuously (75% of mono-
therapy dose) would lead to more toxicity than PVI 5FU
200mgm
 2. The purpose of this study was, therefore, to establish
the optimal dose of X in the initial phase of this randomised trial
by incorporating a dose escalation/de-escalation. We report the
results of this initial phase and the subsequent planned second
interim analysis.
PATIENTS AND METHODS
Study design
The study uses a two by two randomisation to compare X with PVI
5FU and O with cisplatin. The first 80 pts were randomised in a
pilot phase II study, permitting dose escalation/de-escalation in the
event of protocol-defined differences in fluoropyrimidine-depen-
dent Common Toxicity Criteria (CTC) grade 3/4 toxicity in the
X study arms. Fluoropyrimidine-related toxicity (stomatitis,
palmar-plantar erythema (PPE) and diarrhoea) was analysed in a
first planned interim analysis, according to fluoropyrimidine
containing regimen. It was planned that if the grade 3/4 fluoro-
pyrimidine-related toxicity of this dose of X was o10%, the dose
of X would be increased by 25%, if the grade 3/4 fluoropyrimidine
toxicity was 11–29%, the dose would remain unchanged and if it
was 430% the dose would be reduced by 25%. Following
determination of the dose of X to be used in the chemotherapy
combinations (first interim analysis), the multicentre phase III
trial was opened to recruitment and a second interim analysis was
planned at 200 pts. This paper reports the results of the first and
second preplanned interim analyses. Figure 1 summarises the trial
design employed.
Patient eligibility
Patients were required to have histologically verified locally
advanced or metastatic adenocarcinoma, squamous cell or
undifferentiated carcinoma of the oespohagus, oesophagogastric
junction (OGJ) or stomach. The primary tumour was classified
as inoperable on the basis of either findings at laparotomy or
computed tomography (CT) scan and endoscopic ultrasound
results. Patients could not have received any previous chemother-
apy or radiotherapy unless the latter was adjuvant treatment with
relapse outside the radiotherapy field. Patients were required
to have adequate bone marrow (platelets4100 10
9l
 1, WBC
count43 10
9l
 1), renal (glomerular filtration rate X60mlmin
 1
and serum creatinine within normal range) and hepatic (bilirubin
o2  upper limit of normal range) function, Eastern Cooperative
Oncology Group performance status 0–2, life expectancy of at least
3 months and no concurrent uncontrolled medical illness. If there
was a suspicion of left ventricular dysfunction, amultigated cardiac
scan was performed and pts were excluded if this was below the
reference range for the institution. The study was approved by the
Scientific and Research Ethics Committees of the participating
institutions and all participants gave written informed consent
before entering the study.
Pretreatment evaluation
A full history was taken and an examination was performed on pts
prior to treatment. Baseline full blood count, clotting screen, urea
and electrolytes, liver function tests and carcinoembryonic antigen
were performed in all pts. All pts had a baseline CXR and CT scan
of chest, abdomen and pelvis within 28 days of commencing
treatment. Upper GI endoscopy was performed at baseline unless
pts had a histological diagnosis obtained at a laparotomy; baseline
EDTA clearance or 24h urinary creatinine clearance was measured
prior to randomisation and baseline QOL was measured using the
European Organisation for Research and Treatment of Cancer
(EORTC) core 30 questionnaire.
Study protocol
Dual lumen Hickman lines were inserted via the Seldinger
technique, under local anaesthetic, in patient’s randomised to
either of the PVI 5FU containing combinations. On the day of the
insertion of the Hickman line, pts were started on warfarin
1mgday
 1 as prophylaxis for line-related thrombosis. The four
arms of treatment were as follows:
ECF regimen: Epirubicin 50mgm
 2 i.v. bolus every 3 weeks,
cisplatin 60mgm
 2 with standard hydration every 3 weeks
(Findlay et al, 1994), 5FU 200mgm
 2 daily by continuous infusion
via central line.
EOF regimen: Epirubicin 50mgm
 2 i.v. bolus every 3 weeks,
O 130mgm
 2 i.v. infusion over 2h every 3 weeks, 5FU 200mgm
 2
daily by continuous infusion via central line.
ECX regimen:E p i r u b i c i n5 0 m g m
 2 i.v. bolus every 3 weeks,
cisplatin 60mgm
 2 with standard hydration every 3 weeks (Findlay
et al, 1994), X 500–625mgm
 2b.i.d.
 1 orally continuously.
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 2 i.v. bolus every 3 weeks, O
130mgm
 2 i.v. infusion over 2h every 3 weeks, X 500–
625mgm
 2b.i.d.
 1 orally continuously.
Antiemetics were routinely administered and it was recom-
mended to participating centres that a 5HT3 antagonist and
dexamethasone 8mg i.v. be given prechemotherapy and
dexamethasone 4mg p.o. tds for 2 days and metoclopramide
10mg tds for 3 days postchemotherapy. Planned treatment
duration was 24 weeks. Response was evaluated at 12 and 24
weeks.
Evaluation of toxicity
Toxicity was graded according to the National Cancer Institute
common toxicity criteria (CTC) version 2. Dose modifications for
ECF were made according to previously published guidelines
(Findlay et al, 1994). Dose modifications of the E, cisplatin and PVI
5-FU in the EOF, ECX and EOX regimens were made according
to the guidelines for ECF. Oxaliplatin was delayed for 1 week if
neutrophil count o1.0 10
9l
 1, platelet count o75 10
9l
 1 or
the patient had persistent grade 1 or 2 neuropathy. After recovery
from grade 2–4 thrombocytopenia or grade 3/4 neutropenia, the
dose of O was reduced to 100mgm
 2. On recovery of persistent
grade 1/2 neuropathy between cycles or grade 3/4 neuropathy for
7–14 days, the dose of O was dose reduced to 100mgm
 2. In the
event of persistent grade 3/4 neuropathy, further O was omitted
and carboplatin could be substituted at the investigators discre-
tion. If laryngeal dysaesthesia occurred, subsequent O was
administered as a 6-h infusion. If grade 3/4 diarrhoea or stomatitis
occurred despite appropriate fluoropyrimidine dose reductions,
subsequent O was reduced to 100mgm
 2. Capecitabine was
stopped if pts developed grade 2–3 stomatitis, diarrhoea or nausea
and vomiting. If grade 3 toxicity was controlled adequately within
2 days and on resolution of grade 2 toxicity, X was continued at full
dose. If grade 2 toxicity occurred a second time, X was dose
reduced by 25%, a third time by 50% and if it occurred a fourth
time treatment was discontinued. If grade 3 toxicity took longer
than 2 days to resolve, X was dose reduced by 25%. If grade 3
toxicity occurred a second time X was dose reduced by 50% and
discontinued if it occurred a third time. If grade 4 stomatitis,
diarrhoea or nausea and vomiting occurred, X could either be
discontinued or dose reduced by 50%, at the investigator’s
discretion. For X associated PPE, pyridoxine 50mg tds was
commenced and the following modifications were made: grade
1 – no modification, grade 2 – X stopped until resolution and then
dose reduced by 15%, grade 3 – X stopped until resolution and
then dose reduced by 30%, for recurrent grade 3 – X stopped until
resolution and then dose reduced by 50%.
Assessment of response
Response is assessed according to the revised WHO criteria with
RECIST guidelines (Therasse et al, 2000). A complete response
(CR) is the disappearance of all target lesions. A partial response
(PR) is at least a 30% decrease in the sum of the longest diameter
of target lesions, taking as reference the baseline sum longest
diameter. Progressive disease is at least a 20% increase in the sum
of the longest diameter of a target lesion, taking as reference the
smallest sum longest diameter recorded since the treatment started
or the appearance of one or more new lesions. Stable disease is
neither sufficient shrinkage for a partial response, nor sufficient
increase to qualify for progressive disease, taking as reference the
smallest sum longest diameter since the treatment started.
Endoscopic response is used to assess the primary tumour: CR is
no evidence of endoluminal disease and negative histology on
biopsy; PR in the primary site must have CT evidence of a PR and
50% reduction in the endoscopic appearances of the tumour; SD
must be shown on CT scanning; PD at endoscopy classifies overall
as PD regardless of response at other evaluable sites.
Patients completed the EORTC QLQ-C30 version 3.0 QOL
assessment prior to randomisation and at 3, 6, 9 and 12 months
(Aaronson et al, 1993).
Protocol amended  
Study expanded to >20 centres
Total number of patients in second 
interim analysis 
n=204
Trial continues to 
1000 patients 
Second interim analysis  
capecitabine dose  
625 mg m–2 bd–1 
Capecitabine dose escalated  
625 mg m–2 bd–1
Randomised phase II pilot study  
four centres  
80 pts  
Capecitabine dose 500 mg m–2 bd–1 
First interim analysis
Figure 1 Trial design.
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The primary end point of this phase III trial is overall survival and
secondary end points are failure-free survival, response, duration
of response, time to progression, toxicity and QOL. Patient
numbers are based on a 1-year survival of 35% for ECF. A
planned total of 1000 pts will be randomised allowing noninfer-
iority to be demonstrated. An improvement in 1-year survival with
any of the joint arm combinations (e.g. ECFþEOF vs ECXþEOX)
from 35 to 44% could be detected with at least 80% power, or for
an improvement from 35 to 45% with at least 90% power (two-
sided test, alpha 5%). An improvement in 1-year survival with any
of the combinations could be detected from 35 to 46% with 90%
(two-sided test, alpha¼5%). Randomisation is allocated by
telephone, and is stratified for performance status, centre and
locally advanced vs metastatic disease. We are now reporting the
two planned interim analyses within this study.
RESULTS
A total of 204 pts were randomised from 18 oncology centres in the
UK between June 2000 and October 2002. The first 80 pts were
recruited from four centres and in October 2001, the toxicity data
on these pts was analysed and presented to the data monitoring
committee (first planned interim analysis). Of the 204 pts, two
were ineligible (one had a synchronous lung primary, one was
unable to start treatment within 30 days of baseline CT evaluation),
three were randomised but did not receive treatment (one patient
withdrew consent and two deteriorated clinically and were
withdrawn from the study prior to starting treatment) and one
patient received treatment in violation with the protocol. A total
of 198 pts were, therefore, evaluable for toxicity and response. In
total, 53 pts were randomised to ECF, 48 to ECX, 55 to EOF and 48
to EOX. Treatment groups were well balanced for patient
characteristics (Table 1).
In the first planned interim analysis, the first 80 pts were
analysed for toxicity. Fluoropyrimidine-related toxicity (stomatitis,
palmar-plantar erythema (PPE) and diarrhoea) was analysed
according to fluoropyrimidine-containing regimen. The grade 3/4
fluoropyrimidine-related toxicity, in pts receiving X 500mgm
 2
b.i.d., was 5.1%; hence, the dose of X was escalated to 625mgm
 2
b.i.d. (Tebbutt et al, 2002). The trial protocol was amended to
include this dose escalation and ethical approval was obtained by
all the participating centres. The second interim analysis was
performed when 204 pts had been recruited. Figure 2 illustrates the
number of pts receiving each of the fluoropyrimidine doses: 103
pts received F 200mgm
 2day
 1, 60pts X 500mgm
 2b.i.d.
 1 and
35pts X 625mgm
 2b.i.d.
 1
Toxicity
Median number of chemotherapy cycles administered was 6 in
each of the treatment arms. Grade 3/4 fluoropyrimidine-related
Table 1 Patient characteristics
No. of patients
Treatment arm ECF EOF ECX EOX
Randomisation (n) 5 35 54 84 8
Age (years)
Median 64 61 62 64
Range 40–77 45–76 34–81 37–79
Sex
Female 9 8 14 12
Male 39 40 41 41
Performance status
0/1 46 48 42 42
27 7 6 6
Primary site
Oesophagus 21 20 13 14
OGJ 19 15 16 15
Gastric 12 20 18 19
Unknown 1 0 1 0
Histology
Adenocarcinoma 44 48 41 41
Squamous carcinoma 5 6 6 5
Other 3 1 0 1
Unknown 1 0 1 0
Disease status
Locally advanced 15 11 12 17
Metastatic 38 44 36 31
Ineligible 1 0 1 0
Randomised but not treated 3 0 0 0
ECF¼epirubicin, cisplatin, 5-fluorouracil; ECX¼epirubicin, cisplatin, capecitabine;
EOF¼epirubicin, oxaliplatin, 5-fluorouracil; EOX¼epirubicin, oxaliplatin, capecita-
bine; OGJ¼oesophagogastric junction.
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Figure 2 Number of patients and fluoropyrimidine dose. Key: X(500)¼capecitabine 500mgm
 2b.i.d.
 1. X(625)¼capecitabine 625mgm
 2b.i.d.
 1.
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stoxicity (estimated by patient not cycle) according to regimen
and dose of fluoropyrimidine is shown in Table 2. The overall
percentage of grade 3/4 fluoropyrimidine-related toxicity in pts
receiving 5FU 200mgm
 2day
 1 was 13.7% (95% CI 7.4–22%), for
pts receiving X 500mgm
 2 b.i.d. 8.4% (95% CI 2.8–18.7) and for
pts receiving X 625mgm
 2 b.i.d. 14.7% (95% CI 4.9–31). All other
toxicity was predictable and is shown in Table 3, according to
treatment arm and in Table 4 according to treatment arm and dose
of fluoropyrimidine.
Dose intensity
There were no significant differences in the dose intensity of
fluoropyrimidine, E or platinum agent between the four treatment
arms. The dose intensity of the drugs in ECF was E 90.7%, cisplatin
91.9%, 5FU 88.6%; for ECX it was E 90.3%, cisplatin 87.5%,
X 87.1%; for EOF it was E 90%, O 89.4%, 5FU 82.1%; for EOX it
was E 87.5%, O 87.1%, X 83.3%. Dose intensity according to
fluorpyrimidine dosage is shown in Table 5.
Response
Of the 204 patient’s randomised, 198 pts received chemotherapy
within the clinical trial. Two pts had nonevaluable disease and
therefore 196 pts were included in the response analysis on 12th
May 2003. Objective response rates were seen in 15 pts (one CR, 14
PRs) treated with ECF for a response rate of 31%, 21 pts (three
CRs, 18 PRs) treated with EOF for a response rate of 39%, 16 pts
(four CRs, 12 PRs) treated with ECX for a response rate of 35% and
23 pts (one CR, 22 PRs) treated with EOX for a response rate of
48% (Table 6). The corresponding rates of progressive disease
(PD) were 27% with ECF, 20% with EOF, 24% with ECX and 15%
with EOX. There were 18 pts (three ECF, seven EOF, five ECX and
three EOX) in whom no assessment was available. Of the eight pts
Table 2 Fluoropyrimidine toxicity according to treatment arm and dose of fluoropyrimidine
Number of patients (%)
Toxicity (grade 3/4) ECF 200 EOF 200 ECX 500 EOX 500 ECX 625 EOX 625
Stomatitis 0 (0) 5 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Palmar-plantar erythema 2 (4) 1 (2) 1 (4) 2 (6) 3 (16) 1 (6)
Diarrhoea 1 (2%) 5 (10) 0 (0) 2 (6) 0 (0) 1 (6)
Any 5-FU-related toxicity 13 (13.7) 5 (8.4) 5 (14.7)
95% CI 7.4–22 95% CI 2.8–18.7 95% CI 4.9–31
ECF¼epirubicin, cisplatin, 5-fluorouracil; ECX¼epirubicin, cisplatin, capecitabine; EOF¼epirubicin, oxaliplatin, 5-fluorouracil; EOX¼epirubicin, oxaliplatin, capecitabine.
Table 3 Non-fluoropyrimidine toxicity
ECF EOF ECX EOX
Toxicity (grade 3/4) No. of pts/total % No. of pts/total % No. of pts/total % No. of pts/total %
Nausea
a 2/47 4 7/50 14 1/43 2 4/48 8
Alopecia
b 21/47 50 18/50 36 17/43 40 13/48 27
Lethargy 8/46 17 10/50 20 4/43 9 8/48 17
Peripheral neuropathy
a 0/47 0 3/50 6 1/43 2 2/48 4
Neutropenia 16/47 34 12/49 24 16/41 39 19/48 40
Thrombocytopenia
a 2/47 4 4/49 8 4/41 10 3/48 6
Infection
a 6/47 13 10/50 20 2/43 5 6/48 12
Febrile neutropenia 2/24 8 4/29 14 1/24 5 3/30 10
Anaemia 8/47 17 2/49 4 3/41 7 4/48 8
aNo grade 4 toxicity.
bCTC grade 2 alopecia. Pts¼patients; ECF¼epirubicin, cisplatin, 5-fluorouracil; ECX¼epirubicin, cisplatin, capecitabine; EOF¼epirubicin, oxaliplatin, 5-
fluorouracil; EOX¼epirubicin, oxaliplatin, capecitabine.
Table 4 Non-fluoropyrimidine toxicity according to fluoropyrimidine dose
ECF 200 EOF 200 ECX 500 EOX 500 ECX 625 EOX 625
Toxicity (grade 3/4) No. of pts/total % No. of pts/total % No. of pts/total % No. of pts/total % No. of pts/total % No. of pts/total %
Nausea
a 2/47 4 7/50 14 1/27 4 2/32 6 0/16 0 2/16 12
Alopecia
b 21/47 50 18/50 36 12/27 44 10/32 31 5/16 31 3/16 19
Lethargy 8/46 17 10/50 20 3/27 11 5/32 16 1/16 6 3/16 19
Peripheral neuropathy
a 0/47 0 3/50 6 1/27 4 0/32 0 0/16 0 2/16 12
Neutropenia 16/47 34 12/49 24 9/25 36 15/32 46 6/15 40 4/16 25
Thrombocytopenia
a 2/47 4 4/49 8 4/26 15 2/32 6 0/15 0 1/16 6
Infection
a 6/47 13 10/50 20 1/27 4 2/32 6 1/16 6 4/16 25
Febrile neutropenia 2/24 8 4/29 14 1/10 10 0/14 0 0/14 0 3/16 19
Anaemia 8/47 17 2/49 4 2/26 8 3/32 9 1/15 7 1/16 6
aNo grade 4 toxicity.
bCTC grade 2 alopecia. Pts¼patients; ECF¼epirubicin, cisplatin, 5-fluorouracil; ECX¼epirubicin, cisplatin, capecitabine; EOF¼epirubicin, oxaliplatin, 5-
fluorouracil; EOX¼epirubicin, oxaliplatin, capecitabine.
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swho achieved a CR, four were achieved after downstaging
chemotherapy and surgery.
The objective response rates of patients receiving fluoropyri-
midine or platinum agent are shown Tables 7 and 8, respectively.
Objective responses were seen in 36 pts (four CRs, 32 PRs) treated
in either of the two 5FU-containing arms (ECF þEOF) for a
response rate of 36%, and in 39 pts (five CRs, 34 PRs) treated in
either of the two X-containing arms (ECXþEOX) for a response
rate of 41%. Objective responses were seen in 31 pts (five CRs, 26
PRs) treated in either of the cisplatin-containing arms (ECFþECX)
for a response rate of 33%, and in 44 pts (four CRs. 40 PRs) treated
in either of the O-containing arms (EOFþEOX) for a response
rate of 43%.
DISCUSSION
The purpose of the planned interim analyses presented in this
paper was to establish the optimal dose of continuously
administered X to be used in combination with either E and
cisplatin or E and O in pts with advanced OG cancer, and to
confirm the safety of any dose adjustment. The results of the first
interim analysis demonstrated grade 3/4 fluoropyrimidine toxicity
in 5.1% of pts receiving X 500mgm
 2b.i.d.
 1 (Tebbutt et al, 2002).
This resulted in the protocol planned dose escalation of X from
500 to 625mgm
 2b.i.d.
 1. The second analysis, performed when
204 pts had been randomized, confirmed that the dose of
625mgm
 2b.i.d.
 1 was safe. In all, 14.7% of pts treated with
X 625mgm
 2b.i.d.
 1 experienced grade 3/4 fluoropyrimidine-
related toxicity, which parallels that of PVI 5FU (13.7%),
confirming that this is the optimal dose of X to be used in
combination with either E and cisplatin or E and O.
A previous phase I study has evaluated the combination of
X with E 50mgm
 2 and C 60mgm
 2, in pts with advanced OG
cancer (Evans et al, 2002). They evaluated the dose-limiting
toxicity (DLT) and maximum tolerated dose of X with escalations
of X up to 1250mgm
 2b.i.d.
 1 D1–14 with 7 days rest. The
recommended dose of X for use on an intermittent schedule in
combination with E and cisplatin was 1000mgm
 2b.i.d.
 1. There
have been no phase I studies looking at this combination using
a continuous schedule of X; however, the results of our study have
identified X 625mgm
 2b.i.d.
 1 to be the optimal dose in both
an ECX and EOX regimen based on the similar incidence of
fluoropyrimidine-related toxicity (13.7% in 5FU-containing arms
and 14.7% in X 625mgm
 2b.i.d.
 1-containing arms). The non-
fluoropyrimidine-related toxicity in all arms of this study was
Table 5 Dose intensity of chemotherapy agents received according to fluoropyrimidine and dose
% of chemotherapy received
No. of pts 5FU/capecitabine (%) Epirubicin (%) Platinum agent (%)
5FU 200mgm
 2 104 85.2 90.3 90.6
Capecitabine 500mgm
 2b.i.d.
 1 59 87.2 88.9 87.8
Capecitabine 625mgm
 2b.i.d.
 1 35 81.8 88.8 86.4
Pts¼patients; ECF¼epirubicin, cisplatin, 5-fluorouracil (5FU); ECX¼epirubicin, cisplatin, capecitabine; EOF¼epirubicin, oxaliplatin, 5-fluorouracil; EOX¼epirubicin, oxaliplatin,
capecitabine.
Table 6 Response rates according to treatment arm
ECF EOF ECX EOX
No. of pts % No. of pts % No. of pts % No. of pts %
C R 12364912
PR 14 29 18 33 12 26 22 46
Overall (CR+PR) 15 31 21 39 16 35 23 48
95% CI (18.7–46.3) (25.9–53.1) (21.4–50.3) (33.3–62.8)
Stable disease 17 36 16 30 14 30 15 31
PD 13 27 11 20 11 24 7 15
No assessment available 3 6 6 11 5 11 3 6
Pts¼patients; ECF¼epirubicin, cisplatin, 5-fluorouracil; ECX¼epirubicin, cisplatin, capecitabine; EOF¼epirubicin, oxaliplatin, 5-fluorouracil; EOX¼epirubicin, oxaliplatin,
capecitabine; CR¼complete response; PR¼partial response; PD¼progressive disease; 95% CI¼95% confidence interval.
Table 7 Response rates of patients receiving fluoropyrimidine treatment
5-FU arms Capecitabine arms
No. of pts % No. of pts %
C R 4455
PR 32 32 34 36
Overall 36 36 39 41
95% CI (26.6–46.2) (31.4–52.1)
SD 33 32 29 30
PD 24 24 18 19
No assessment available 9 8 8 10
Pts¼patients; CR¼complete response; PR¼partial response; PD¼progressive
disease; SD¼stable disease; 95% CI¼95% confidence interval.
Table 8 Response rates of patients receiving platinum treatment
Cisplatin arms Oxaliplatin arms
No. of pts % No. of pts %
C R 5544
PR 26 28 40 39
Overall 31 33 44 43
95% CI (23.6–43.3) (34.1–54.3)
SD 31 33 31 30
PD 24 26 18 18
No assessment available 8 8 9 9
Pts¼patients; CR¼complete response; PR¼partial response; PD¼progressive
disease; SD¼stable disease; 95% CI¼95% confidence interval.
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spredictable and consistent with previous clinical trials (Ross
et al, 2002). The rates of grade 3/4 febrile neutropenia were 8%
ECF, 14% EOF, 5% ECX and 10% EOX. However, the rate of
grade 3/4 febrile neutropenia in pts receiving EOX where
X¼625mgm
 2b.i.d.
 1 was 19% (three out of 16 pts), which is
higher than any of the other arms. This may be due to relatively
small patient numbers; however, the final analysis of this study will
establish whether this is significant.
The primary end point of this study is to compare the overall
survival in the four treatment arms and thus no survival data
will be analysed until accrual is complete. The response rates
indicate that X has efficacy similar to 5-FU and that O appears
to have promising activity in advanced OG cancer. It was not in
the remit of this analysis to compare response rates and to draw
firm conclusions from them at this stage would be erroneous.
Patient preference is for oral chemotherapy regimen (Borner
et al, 2002) and with the associated complications of the
indwelling central venous catheter necessary with PVI-5FU,
the replacement of 5FU with X would clearly be one of
considerable benefit to pts.
In summary, we have presented the results of two planned
interim analyses within a multicentre randomised study evaluating
the role of X and O in advanced OG cancer. The results clearly
confirm the safety of the dose escalation of X and demonstrate
X 625mgm
 2b.i.d.
 1 continuously to be the dose that should be
used in combination with the EC and EO regimens. In addition,
our results show that X has similar efficacy to PVI 5-FU. The trial
will continue to accrue to a planned target of 1000 pts.
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